Inter Partes Review

PENDING IPRs

Rituxan® (Rituximab)

  • IPR2016-01614
  • IPR2016-01667
  • IPR2017-01093
    • Patent Number: 8,329,172
    • Patent Owner: Biogen
    • Petitioner: Celltrion
    • Status:  Institution Decision Pending
    • Petition
  • IPR2017-01094
    • Patent Number: 8,557,244
    • Patent Owner: Biogen
    • Petitioner: Celltrion
    • Status: Institution Decision Pending
    • Petition
  • IPR2017-01095
    • Patent Number: 9,296,821
    • Patent Owner: Biogen
    • Petitioner: Celltrion
    • Status:  Institution Decision Pending
    • Petition
  • IPR2017-01227
    • Patent Number: 7,682,612
    • Patent Owner: Genentech
    • Petitioner: Celltrion
    • Status:  Institution Decision Pending
    • Petition
  • IPR2017-01229
    • Patent Number: 8,206,711
    • Patent Owner: Genentech
    • Petitioner: Celltrion
    • Status: Institution Decision Pending
    • Petition
  • IPR2017-01230
    • Patent Number: 7,682,612
    • Patent Owner: Genentech
    • Petitioner: Celltrion
    • Status: Institution Decision Pending
    • Petition
  • IPR2017-01115
    • Patent number: 7,820,161
    • Patent Owner: Genentech
    • Petitioner: Pfizer
    • Status: Institution Decision Pending
    • Petition
  • IPR2017-01166
    • Patent number: 8,329,172
    • Patent Owner:  Biogen, Inc.
    • Petitioner: Pfizer
    • Status: Institution Decision Pending
    • Petition
  • IPR2017-01167
    • Patent number: 8,577,244
    • Patent Owner:  Biogen, Inc.
    • Petitioner: Pfizer
    • Status: Institution Decision Pending
    • Petition
  • IPR2017-01168
    • Patent number: 8,821,873
    • Patent Owner: Biogen, Inc.
    • Petitioner: Pfizer
    • Status: Institution Decision Pending
    • Petition

Humira® (adalimumab)

General Biologic Patents

  • IPR2016-01608
  • IPR2016-00258
  • IPR2017-01129
    • Patent number: 8,679,487
    • Patent Owner: Immunex Corp.
    • Petitioner:  Sanofi-Aventis, Genzyme, and Regeneron
    • Status:  Institution Decision Pending
    • Petition
  • IPR2017-01252
    • Patent number: 6,946,292
    • Patent Owner:  Kyowa Kakko Kirin Co., Ltd.
    • Petitioner: Aragen Bioscience, Inc.
    • Status: Institution Decision Pending
    • Petition
  • IPR2017-01254
    • Patent number: 8,067,232
    • Patent Owner: Kyowa Hakko Kirin Co., Ltd.
    • Petitioner: Aragen Bioscience, Inc.
    • Status: Institution Decision Pending
    • Petition
  • IPR2017-01262
    • Patent number: 7,425,446
    • Patent Owner: Kyowa Hakko Kirin Co., Ltd.
    • Petitioner: Aragen Bioscience, Inc.
    • Status: Institution Decision Pending
    • Petition
  • IPR2017-01357
    • Patent Number: 7,332,289
    • Patent Owner: Chugai Pharmaceutical Co., Ltd.
    • Petitioner:  Pfizer, Inc.
    • Status: Institution Decision Pending
    • Petition
  • IPR2017-01358
    • Patent Number: 7,927,815
    • Patent Owner: Chugai Pharmaceutical Co., Ltd.
    • Petitioner: Pfizer, Inc.
    • Status: Institution Decision Pending
    • Petition

Cabilly Patents

Neulasta (pegfilgrastim)

Herceptin (trastuzumab)

  • IPR2016-01693
  • IPR2016-01694
  • IPR2016-01837
  • IPR2017-00739
  • IPR2017-00737
  • IPR2017-00731
  • IPR2017-00805
  • IPR2017-00804
  • IPR2017-00959
    • Patent number: 8,591,897
    • Patent Owner: Genentech
    • Petitioner: Celltrion
    • Status: Institution Decision Pending
    • Petition
  • IPR2017-01121
    • Patent number: 7,846,441
    • Patent Owner: Genentech
    • Petitioner: Celltrion
    • Status: Institution Decision Pending
    • Petition
  • IPR2017-01122
    • Patent number: 7,892,549
    • Patent Owner: Genentech
    • Petitioner: Celltrion
    • Status: Institution Decision Pending
    • Petition
  • IPR2017-01139
    • Patent number: 6,627,196
    • Patent Owner: Genentech
    • Petitioner: Celltrion
    • Status: Institution Decision Pending
    • Petition
  • IPR2017-01140
    • Patent number: 7,371,379
    • Patent Owner: Genentech
    • Petitioner: Celltrion
    • Status: Institution Decision Pending
    • Petition
  • IPR2017-01374
    • Patent number: 6,407,213
    • Patent Owner: Genentech
    • Petitioner: Celltrion
    • Status: Institution Decision Pending
    • Petition
  • IPR2017-01373
    • Patent number: 6,407,213
    • Patent Owner: Genentech
    • Petitioner: Celltrion
    • Status: Institution Decision Pending
    • Petition 
  • IPR2017-01488
    • Patent number: 6,407,213
    • Patent Owner: Genentech
    • Petitioner: Pfizer, Inc.
    • Status: Institution Decision Pending
    • Petition
  • IPR2017-01489
    • Patent number: 6,407,213
    • Patent Owner: Genentech
    • Petitioner: Pfizer, Inc.
    • Status: Institution Decision Pending
    • Petition

Avastin (bevacizumab)

Lantus (Insulin Glargine)

  • IPR2017-01526
    • Patent Number: 7,476,652
    • Patent Owner: Sanofi
    • Petitioner: Mylan
    • Status: Institution Decision Pending
    • Petition
  • IPR2017-01528
    • Patent Number: 7,713,930
    • Patent Owner: Sanofi
    • Petitioner: Mylan
    • Status: Institution Decision Pending
    • Petition

TERMINATED IPRS

Rituximab (Rituxan)

  • IPR2015-00417
  • IPR2015-00415
  • IPR2015-00418
  • IPR2015-01744
    • Patent number: 7,820,161
    • Patent owner: Genentech, Inc.
    • Petitioner: Celltrion
    • Status: Terminated prior to institution following motion to dismiss by petitioner
    • Petition
  • IPR2015-01733
    • Patent number: 7,976,838
    • Patent owner: Genentech, Inc.
    • Petitioner: Celltrion
    • Status: Terminated prior to institution following motion to dismiss by petitioner
    • Petition

Humira® (adalimumab)

Cabilly Patents

Enbrel® (etanercept)

Orencia® (abatacept)

Tysabri (natalizumab)

Download PDF